Evrysdi (risdiplam) for oral solution, 60 mg/80mL (0.75mg/mL), 80 mL total volume after constitut...
FDA Drug Recall #D-0357-2021 — Class III — April 20, 2021
Recall Summary
| Recall Number | D-0357-2021 |
| Classification | Class III — Low risk |
| Date Initiated | April 20, 2021 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Genentech Inc |
| Location | South San Francisco, CA |
| Product Type | Drugs |
| Quantity | 2,627 bottles |
Product Description
Evrysdi (risdiplam) for oral solution, 60 mg/80mL (0.75mg/mL), 80 mL total volume after constitution, Rx only, Distributed by: Genentech, Inc. NDC:50242-175-05
Reason for Recall
Defective Container: complaints received regarding some incorrect press-in-bottle-adapters (PIBA), the incorrect PIBAs have a female instead of male fit so they cannot be used in combination with co-packed syringes.
Distribution Pattern
Distributed Nationwide in the USA.
Lot / Code Information
Lot #: B1001B05; B1001B08, Exp. Feb-2022
Other Recalls from Genentech Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0025-2023 | Class III | Susvimo (ranibizumab injection), 100mg/mL, sold... | Oct 18, 2022 |
| D-0650-2021 | Class II | Xolair (omalizumab) Injection, 150 mg/1 mL, 1 p... | Jun 9, 2021 |
| D-087-2013 | Class II | Nutropin AQ NuSpin 20 (somatropin (rDNA origin)... | Sep 20, 2012 |
| D-088-2013 | Class II | Nutropin AQ NuSpin 10 (somatropin (rDNA origin)... | Sep 20, 2012 |
| D-135-2013 | Class I | Trastuzumab Kit containing 1 vial Trastuzumab (... | Jul 30, 2012 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.